1. Home
  2. SUPN vs CMPR Comparison

SUPN vs CMPR Comparison

Compare SUPN & CMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • CMPR
  • Stock Information
  • Founded
  • SUPN 2005
  • CMPR 1994
  • Country
  • SUPN United States
  • CMPR Ireland
  • Employees
  • SUPN N/A
  • CMPR N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • CMPR Publishing
  • Sector
  • SUPN Health Care
  • CMPR Consumer Discretionary
  • Exchange
  • SUPN Nasdaq
  • CMPR Nasdaq
  • Market Cap
  • SUPN 1.9B
  • CMPR 2.0B
  • IPO Year
  • SUPN 2012
  • CMPR N/A
  • Fundamental
  • Price
  • SUPN $36.43
  • CMPR $70.07
  • Analyst Decision
  • SUPN Hold
  • CMPR Strong Buy
  • Analyst Count
  • SUPN 1
  • CMPR 2
  • Target Price
  • SUPN $36.00
  • CMPR $114.50
  • AVG Volume (30 Days)
  • SUPN 348.4K
  • CMPR 130.3K
  • Earning Date
  • SUPN 02-25-2025
  • CMPR 01-29-2025
  • Dividend Yield
  • SUPN N/A
  • CMPR N/A
  • EPS Growth
  • SUPN 130.79
  • CMPR N/A
  • EPS
  • SUPN 1.07
  • CMPR 5.90
  • Revenue
  • SUPN $651,972,000.00
  • CMPR $3,339,531,000.00
  • Revenue This Year
  • SUPN $7.82
  • CMPR $7.63
  • Revenue Next Year
  • SUPN N/A
  • CMPR $5.45
  • P/E Ratio
  • SUPN $34.05
  • CMPR $11.88
  • Revenue Growth
  • SUPN 6.79
  • CMPR 6.57
  • 52 Week Low
  • SUPN $25.53
  • CMPR $58.05
  • 52 Week High
  • SUPN $39.37
  • CMPR $104.92
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 52.26
  • CMPR 31.46
  • Support Level
  • SUPN $35.73
  • CMPR $70.22
  • Resistance Level
  • SUPN $37.34
  • CMPR $85.56
  • Average True Range (ATR)
  • SUPN 1.20
  • CMPR 2.87
  • MACD
  • SUPN -0.01
  • CMPR -0.78
  • Stochastic Oscillator
  • SUPN 69.02
  • CMPR 8.73

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About CMPR Cimpress plc (Ireland)

Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.

Share on Social Networks: